On October 2, 2024, Mylan Pharmaceuticals and Novo Nordisk reached a confidential settlement agreement regarding the launch date of generic versions of Ozempic (semaglutide). Although the agreement remains confidential at this time, it is likely that the agreement will allow Mylan to launch some strengths of generic semaglutide in the second half of 2031 or first half of 2032. The glucagon-like peptide-1 receptor agonist (GLP-1 RA) category includes other medications such as Mounjaro, Rybelsus, Victoza, Bydureon, and Byetta which were all approved under the New Drug Applications which means they will likely have generic versions at the point of patent expiration. Only GLP-1RA, Trulicity, which loses patent in 2027 is considered a biologic and therefore would have biosimilars at loss of exclusivity.
https://medwatch.com/News/Pharma___Biotech/article17516155.ece?utm_content=315936047&utm_medium=social&utm_source=facebook&hss_channel=fbp-886153778131997
